Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly.​

We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system.​

This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases.

Biotechnology

Health Care

Life Sciences

Therapeutics

Greywolf Therapeutics

Greywolf Therapeutics' headquarters in Milton, United Kingdom

Peter Joyce

Darlene Deptula-Hicks

Tom McCarthy

Paul Stainer

Tom Lillie

Andy Page

Description

People (10)

Peter Joyce

Andy Page

Natalie Hyland

Kreshnik Hoxha

Kate Anderton

Martin Quibell

Kris Clark

Paul Stainer

Emma Johnson

Tom McCarthy

Jobs